Scl-Ab reverts pro-osteoclastogenic signalling and resorption in estrogen deficient osteocytes

BACKGROUND: Neutralising antibodies to sclerostin (Scl-Ab) have shown significant potential to induce bone formation and decrease bone resorption, increase strength and substantially reduce fracture risk in animal studies and clinical trials. Mechanical loading negatively regulates sclerostin expres...

Descripción completa

Detalles Bibliográficos
Autores principales: Allison, H., Holdsworth, G., McNamara, L. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643443/
https://www.ncbi.nlm.nih.gov/pubmed/33148174
http://dx.doi.org/10.1186/s12860-020-00322-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7643443/
https://www.ncbi.nlm.nih.gov/pubmed/33148174
http://dx.doi.org/10.1186/s12860-020-00322-w

Ejemplares similares